Dashboard
1
Poor Management Efficiency with a low ROE of 1.43%
- The company has been able to generate a Return on Equity (avg) of 1.43% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Operating profit has grown by an annual rate -17.49% of over the last 5 years
3
With ROE of -0.77%, it has a risky valuation with a 3.08 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
PLN 1,088 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.03
1.10%
2.80
Revenue and Profits:
Net Sales:
49 Million
(Quarterly Results - Mar 2025)
Net Profit:
-25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.4%
0%
-10.4%
6 Months
-13.51%
0%
-13.51%
1 Year
-16.92%
0%
-16.92%
2 Years
22.58%
0%
22.58%
3 Years
25.66%
0%
25.66%
4 Years
-36.06%
0%
-36.06%
5 Years
-51.56%
0%
-51.56%
Celon Pharma SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.90%
EBIT Growth (5y)
-17.49%
EBIT to Interest (avg)
-10.38
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.46
Tax Ratio
23.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.17%
ROE (avg)
1.43%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.08
EV to EBIT
-1158.12
EV to EBITDA
23.37
EV to Capital Employed
3.23
EV to Sales
4.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.14%
ROE (Latest)
-0.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY
Mar'25
Mar'24
Change(%)
Net Sales
49.30
36.30
35.81%
Operating Profit (PBDIT) excl Other Income
-5.30
-9.10
41.76%
Interest
0.50
17.80
-97.19%
Exceptional Items
0.10
3.00
-96.67%
Consolidate Net Profit
-25.10
-15.70
-59.87%
Operating Profit Margin (Excl OI)
-377.00%
-601.00%
22.40%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2025 is 35.81% vs -7.63% in Mar 2024
Consolidated Net Profit
YoY Growth in quarter ended Mar 2025 is -59.87% vs -65.26% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
179.80
167.00
7.66%
Operating Profit (PBDIT) excl Other Income
-27.80
-26.80
-3.73%
Interest
2.50
2.70
-7.41%
Exceptional Items
5.70
8.50
-32.94%
Consolidate Net Profit
-34.40
-28.10
-22.42%
Operating Profit Margin (Excl OI)
-443.10%
-459.90%
1.68%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 7.66% vs 2.71% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -22.42% vs 28.50% in Dec 2023
About Celon Pharma SA 
Celon Pharma SA
Pharmaceuticals & Biotechnology
Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
Company Coordinates 
Company Details
Ul. Ogrodowa 2A, Kielpin , None : 05-092
Registrar Details






